Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MLN-519. Millennium/PAION.

Literature DB >> 12735235

MLN-519. Millennium/PAION.

Abstract

Millennium Pharmaceuticals Inc (formerly LeukoSite Inc) and PAION GmbH are developing MLN-519, a ubiquitin/proteasome enzyme inhibitor, for the potential treatment of inflammatory diseases and stroke. MLN-519 is currently undergoing phase I clinical trials in acute stroke and myocardial infarction, and is poised to enter phase II trials.

Entities: Disease

Mesh：

Substances：

Year: 2003 PMID： 12735235

Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472

Keyword Cloud
Cited

7 in total

1. The treatment of traumatic brain injury with velcade.

Authors: Changsheng Qu; Asim Mahmood; Ruizhuo Ning; Ye Xiong; Li Zhang; Jieli Chen; Hao Jiang; Michael Chopp
Journal: J Neurotrauma Date: 2010-09 Impact factor: 5.269

Review 2. The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.

Authors: Mario Di Napoli; BethAnn McLaughlin
Journal: Curr Opin Investig Drugs Date: 2005-07

MLN-519. Millennium/PAION.

1. The treatment of traumatic brain injury with velcade.

Review 2. The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.

3. Modulation of inflammatory response in sepsis by proteasome inhibition.

4. Effects of proteasome inhibitors MG132, ZL3VS and AdaAhx3L3VS on protein metabolism in septic rats.

Review 5. Proteasome biology and therapeutics in cardiac diseases.

6. Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease.

7. The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research.